173 related articles for article (PubMed ID: 36039386)
1. Structural study of the uPA-nafamostat complex reveals a covalent inhibitory mechanism of nafamostat.
Zhou Y; Wu J; Xue G; Li J; Jiang L; Huang M
Biophys J; 2022 Oct; 121(20):3940-3949. PubMed ID: 36039386
[TBL] [Abstract][Full Text] [Related]
2. Structural Basis of Covalent Inhibitory Mechanism of TMPRSS2-Related Serine Proteases by Camostat.
Sun G; Sui Y; Zhou Y; Ya J; Yuan C; Jiang L; Huang M
J Virol; 2021 Sep; 95(19):e0086121. PubMed ID: 34160253
[TBL] [Abstract][Full Text] [Related]
3. Insights into the serine protease mechanism based on structural observations of the conversion of a peptidyl serine protease inhibitor to a substrate.
Jiang L; Andersen LM; Andreasen PA; Chen L; Huang M
Biochim Biophys Acta; 2016 Mar; 1860(3):599-606. PubMed ID: 26691138
[TBL] [Abstract][Full Text] [Related]
4. The surface of prostate carcinoma DU145 cells mediates the inhibition of urokinase-type plasminogen activator by maspin.
McGowen R; Biliran H; Sager R; Sheng S
Cancer Res; 2000 Sep; 60(17):4771-8. PubMed ID: 10987285
[TBL] [Abstract][Full Text] [Related]
5. A novel serine protease inhibition motif involving a multi-centered short hydrogen bonding network at the active site.
Katz BA; Elrod K; Luong C; Rice MJ; Mackman RL; Sprengeler PA; Spencer J; Hataye J; Janc J; Link J; Litvak J; Rai R; Rice K; Sideris S; Verner E; Young W
J Mol Biol; 2001 Apr; 307(5):1451-86. PubMed ID: 11292354
[TBL] [Abstract][Full Text] [Related]
6. Crystals of urokinase type plasminogen activator complexes reveal the binding mode of peptidomimetic inhibitors.
Zeslawska E; Jacob U; Schweinitz A; Coombs G; Bode W; Madison E
J Mol Biol; 2003 Apr; 328(1):109-18. PubMed ID: 12684001
[TBL] [Abstract][Full Text] [Related]
7. Engineering inhibitors highly selective for the S1 sites of Ser190 trypsin-like serine protease drug targets.
Katz BA; Sprengeler PA; Luong C; Verner E; Elrod K; Kirtley M; Janc J; Spencer JR; Breitenbucher JG; Hui H; McGee D; Allen D; Martelli A; Mackman RL
Chem Biol; 2001 Nov; 8(11):1107-21. PubMed ID: 11731301
[TBL] [Abstract][Full Text] [Related]
8. Nafamostat Mesylate in Combination with the Mouse Amino-Terminal Fragment of Urokinase-Human Serum Albumin Improves the Treatment Outcome of Triple-Negative Breast Cancer Therapy.
Zhou Y; Yu S; Chen D; Li H; Xu P; Yuan C; Jiang L; Huang M
Mol Pharm; 2023 Feb; 20(2):905-917. PubMed ID: 36463525
[TBL] [Abstract][Full Text] [Related]
9. Structure of an affinity-matured inhibitory recombinant fab against urokinase plasminogen activator reveals basis of potency and specificity.
Sevillano N; Bohn MF; Zimanyi M; Chen Y; Petzold C; Gupta S; Ralston CY; Craik CS
Biochim Biophys Acta Proteins Proteom; 2021 Feb; 1869(2):140562. PubMed ID: 33221341
[TBL] [Abstract][Full Text] [Related]
10. Molecular basis of specific inhibition of urokinase plasminogen activator by amiloride.
Jankun J; Skrzypczak-Jankun E
Cancer Biochem Biophys; 1999 Jul; 17(1-2):109-23. PubMed ID: 10738907
[TBL] [Abstract][Full Text] [Related]
11. Structural basis for selectivity of a small molecule, S1-binding, submicromolar inhibitor of urokinase-type plasminogen activator.
Katz BA; Mackman R; Luong C; Radika K; Martelli A; Sprengeler PA; Wang J; Chan H; Wong L
Chem Biol; 2000 Apr; 7(4):299-312. PubMed ID: 10779411
[TBL] [Abstract][Full Text] [Related]
12. A structural mechanism of flavonoids in inhibiting serine proteases.
Xue G; Gong L; Yuan C; Xu M; Wang X; Jiang L; Huang M
Food Funct; 2017 Jul; 8(7):2437-2443. PubMed ID: 28644504
[TBL] [Abstract][Full Text] [Related]
13. A new class of orthosteric uPAR·uPA small-molecule antagonists are allosteric inhibitors of the uPAR·vitronectin interaction.
Liu D; Zhou D; Wang B; Knabe WE; Meroueh SO
ACS Chem Biol; 2015 Jun; 10(6):1521-34. PubMed ID: 25671694
[TBL] [Abstract][Full Text] [Related]
14. Insight to the residue in P2 position prevents the peptide inhibitor from being hydrolyzed by serine proteases.
Xue G; Xie X; Zhou Y; Yuan C; Huang M; Jiang L
Biosci Biotechnol Biochem; 2020 Jun; 84(6):1153-1159. PubMed ID: 32019421
[TBL] [Abstract][Full Text] [Related]
15. A urokinase-type plasminogen activator-inhibiting cyclic peptide with an unusual P2 residue and an extended protease binding surface demonstrates new modalities for enzyme inhibition.
Hansen M; Wind T; Blouse GE; Christensen A; Petersen HH; Kjelgaard S; Mathiasen L; Holtet TL; Andreasen PA
J Biol Chem; 2005 Nov; 280(46):38424-37. PubMed ID: 16141208
[TBL] [Abstract][Full Text] [Related]
16. Regulated localization confers multiple functions on the protease urokinase plasminogen activator.
Wells JM; Strickland S
J Cell Physiol; 1997 May; 171(2):217-25. PubMed ID: 9130470
[TBL] [Abstract][Full Text] [Related]
17. Characterising the Subsite Specificity of Urokinase-Type Plasminogen Activator and Tissue-Type Plasminogen Activator using a Sequence-Defined Peptide Aldehyde Library.
Li CY; de Veer SJ; Law RHP; Whisstock JC; Craik DJ; Swedberg JE
Chembiochem; 2019 Jan; 20(1):46-50. PubMed ID: 30225958
[TBL] [Abstract][Full Text] [Related]
18. Elaborate manifold of short hydrogen bond arrays mediating binding of active site-directed serine protease inhibitors.
Katz BA; Elrod K; Verner E; Mackman RL; Luong C; Shrader WD; Sendzik M; Spencer JR; Sprengeler PA; Kolesnikov A; Tai VW; Hui HC; Breitenbucher JG; Allen D; Janc JW
J Mol Biol; 2003 May; 329(1):93-120. PubMed ID: 12742021
[TBL] [Abstract][Full Text] [Related]
19. Activation of the zymogen to urokinase-type plasminogen activator is associated with increased interdomain flexibility.
Behrens MA; Botkjaer KA; Goswami S; Oliveira CL; Jensen JK; Schar CR; Declerck PJ; Peterson CB; Andreasen PA; Pedersen JS
J Mol Biol; 2011 Aug; 411(2):417-29. PubMed ID: 21669207
[TBL] [Abstract][Full Text] [Related]
20. Structural basis for recognition of urokinase-type plasminogen activator by plasminogen activator inhibitor-1.
Lin Z; Jiang L; Yuan C; Jensen JK; Zhang X; Luo Z; Furie BC; Furie B; Andreasen PA; Huang M
J Biol Chem; 2011 Mar; 286(9):7027-32. PubMed ID: 21199867
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
